Bioject third one fourth revenues increase to $3.

Permit and technology costs were $245,september 30 000 for the one fourth ended, 2011, in comparison to $91,000 in the similar 2010 period. Net gain allocable to common shareholders for the 3rd one fourth of 2011 was $372,000 in comparison to a net reduction allocable to common shareholders of $357,000 in the similar 2010 period. At September 30 Cash, 2011 totaled $1.0 million. Basic and diluted net gain per talk about allocable to common shareholders for the one fourth ended September 30, 2011 was $0.01 per talk about on 18.9 million and 38.2 million weighted average shares outstanding, respectively, in comparison to a net lack of $0.02 per talk about on 17.9 million weighted average shares outstanding for the same amount of 2010.We anticipate initiating a large also, controlled and randomized scientific study for AGS-003 in combination with sunitinib in 2011.’ The study’s major endpoint is to judge scientific activity as measured by goal tumor response. Secondary endpoints included protection, clinical benefit , immunologic response, and evaluation of both progression-free and overall survival.

Chronic kidney disease independently increases mortality risk By Ingrid Grasmo, medwireNews Reporter Findings from two meta-analyses published in The Lancet present that individuals with chronic kidney disease are in high risk for loss of life and end-stage renal disease even if they do not have comorbid hypertension or diabetes.

Other entries from category "prosthetics":

Random entries